Merck out of COVID-19 vaccine race after 'disappointing' trial results - Business Insider

  • 📰 BusinessInsider
  • ⏱ Reading Time:
  • 30 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 15%
  • Publisher: 51%

Business News News

US drug giant Merck drops out the COVID-19 vaccine race, after its 2 vaccine candidates failed to generate immune response

The vaccines were well tolerated in clinical trials, but failed to produce an adequate immune response.Visit Business Insider's homepage for more storiesUS pharma giant Merck has scrapped two coronavirus vaccine candidates after they failed to produce an adequate immune response in early trials, theThe vaccines were generally well tolerated, but worked less well than existing COVID-19 vaccines and immunity from catching the virus, Merck said in the press release.

The results were "disappointing, and a bit of a surprise," Nick Kartsonis, senior vice president of clinical research for infectious diseases and vaccines at Merck Research Laboratories,The studies haven't yet been published in a peer-reviewed journal to be scrutinized. Merck said it would now focus on advancing two experimental treatments for COVID-19 that are in late stage development.

"In the world of pharmaceutical development, a quick kill is not a bad thing because it allows you to reposition and repurpose your assets," Kartsonis

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.

plz investigate ivermectin as a treatment...

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 729. in BUSÄ°NESS

Business Business Latest News, Business Business Headlines